In the bio-tech investment scene,
Hasbro Inc. (NASDAQ:HAS) has experienced a flurry of noteworthy activities. Brokerages and investment companies, including Bridgefront Capital LLC and Castlekeep Investment Advisors LLC, have significantly increased their shareholdings, reflecting a strong
revenue forecast and Q1 results that
exceeded expectations. This has led to a surge in stock prices, further fueled by positive responses from industry figures such as
Jim Cramer, and optimism over Hasbro’s management of tariff impacts. Having said that, the stock has also seen sales from AQR Capital Management LLC and Voya Investment Management LLC, who have offloaded 289,349 and 4,655 shares respectively. Additionally, the company has been cautioned for its dependence on the China supply chain, and tariff-related concerns have been expressed by industry experts. Furthermore, some of Hasbro's financial partners, including First Trust Advisors LP and JPMorgan Chase & Co., have decreased their investments in the company. Despite this,
Hasbro’s future, firmly vested in its ‘
Wizards of the Coast’ product and Disney licensing deal extension, is looking promising.
Hasbro Stocks HAS News Analytics from Thu, 31 Oct 2024 07:00:00 GMT to Sat, 10 May 2025 21:52:06 GMT -
Rating 6
- Innovation 2
- Information 7
- Rumor 5
